Valeant Pharmaceuticals to Acquire Sprout Pharmaceuticals

PRESS RELEASE

LAVAL, Quebec

and

RALEIGH, N.C.

,

Aug. 20, 2015

/PRNewswire/ --

Valeant Pharmaceuticals International, Inc.

(NYSE: VRX) (TSX: VRX) and

Sprout Pharmaceuticals, Inc.

today announced that they have entered into a definitive agreement under which a wholly-owned subsidiary of Valeant will acquire Sprout, on a debt-free basis, for approximately

$1 billion

in cash, plus a share of future profits based upon the achievement of certain milestones.

On

Tuesday, August 18, 2015

, Sprout received approval from the

U.S. Food and Drug Administration

(

FDA

) on its New Drug Application (NDA) for flibanserin, which will be marketed as Addyi in the U.S. Addyi has demonstrated improvements in desire for sex, reducing distress from the loss of sexual desire and increasing the number of satisfying sexual events. Sprout also has global rights for flibanserin. Valeant will leverage its global scale to register flibanserin internationally.

Sprout is passionate about women's sexual health and has focused solely on the delivery of a treatment option for the unmet need of premenopausal women with acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.

Addyi is not indicated for use in postmenopausal women or men or to enhance sexual function. Addyi was approved with a Boxed Warning. Use of Addyi with alcohol increases the risk of severe hypotension and syncope; therefore, alcohol use is contraindicated. Severe hypotension and syncope occurs when Addyi is used with moderate or strong CYP3A4 inhibitors or in patients with hepatic impairment; therefore use of Addyi in patients with hepatic impairment is also contraindicated. Hypotension, syncope and central nervous system (CNS) depression can occur with Addyi alone. The most common adverse reactions are dizziness, somnolence, nausea, fatigue, insomnia and dry mouth.

Valeant expects Addyi to be available in

the United States

in the fourth quarter of 2015 through prescribers and pharmacies that have been certified under the U.S.

FDA's

comprehensive Risk Evaluation and Mitigation Strategy (REMS) program to assure safe use. Following the closing of the transaction, Valeant, under the REMS, will offer physicians and pharmacists the required certification programs for prescribing and dispensing Addyi.

Following the closing of the acquisition, Sprout will remain headquartered in

Raleigh, N.C.

and become a division of Valeant.

Cindy Whitehead

, Chief Executive Officer of Sprout, will join Valeant to lead this division dedicated to the introduction and global commercialization of Addyi, reporting to

Anne Whitaker

, Executive Vice President and Company Group Chairman.

Valeant's Chairman and Chief Executive Officer,

J. Michael Pearson

, said, "Delivering a first-ever treatment for a commonly reported form of female sexual dysfunction gives us the perfect opportunity to establish a new portfolio of important medications that uniquely impact women. We applaud the efforts of the Sprout team to address this important area of unmet need and look forward to working with them to bring the benefits of Addyi to additional markets around the world."

Sprout Chief Executive Officer,

Cindy Whitehead

, said, "I am extremely proud of the commitment and passion of our 34 employees who have been mission driven to get to this breakthrough first for women. This partnership with Valeant allows us the capacity to now ensure broader, more affordable access to all the women who have been waiting for this treatment. Beyond building this in

the United States

, Valeant also offers us a global footprint that could eventually bring Addyi to women across the globe."

"The Valeant team is excited to be a part of the launch of this critically important treatment for women, and I am personally delighted to welcome Cindy and her colleagues at Sprout to Valeant," added

Anne Whitaker

, Executive Vice President and Company Group Chairman. "The Sprout team, along with the healthcare providers involved in the Addyi pivotal clinical trials, has delivered on its promise to provide access to a safe and effective treatment for a condition that affects millions of women."

Under terms of the acquisition agreement, Valeant will pay approximately

$500 million

, subject to customary purchase price adjustments, upon the closing of the transaction and an additional payment in the amount of

$500 million

, payable in the first quarter of 2016, plus a share of future profits based upon the achievement of certain milestones. Valeant expects no impact to 2015 earnings, and moderate accretion to 2016 earnings.

The transaction is subject to customary closing conditions and regulatory approval, including Hart-Scott-Rodino antitrust clearance. The transaction is expected to close in the third quarter of 2015.

Skadden, Arps, Slate, Meagher & Flom LLP

served as Valeant's legal counsel. Sprout was advised by

Sullivan & Cromwell LLP

as its legal counsel and

Perella Weinberg Partners

as its financial advisor.